GLP-1 and Diabetes: Understanding Mechanisms and Advancements in Therapies

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 plays a critical role in glucose regulation and is a target for innovative diabetes therapies. This article reviews GLP-1 mechanisms and current treatments for type 2 diabetes.

# GLP-1 and Diabetes: Understanding Mechanisms and Advancements in Therapies

Introduction

Glucagon-like peptide-1 (GLP-1) is an incretin hormone with significant implications for diabetes management, particularly type 2 diabetes mellitus (T2DM). It enhances insulin secretion, suppresses glucagon, and slows gastric emptying, contributing to improved blood glucose control. This article explores the physiological mechanisms of GLP-1 and highlights current GLP-1-based therapies that are transforming diabetes treatment.

What is GLP-1?

GLP-1 is a peptide hormone secreted by L-cells in the small intestine in response to nutrient ingestion. It belongs to the incretin family of hormones, which amplify insulin secretion from pancreatic beta cells in a glucose-dependent manner. This mechanism helps to regulate postprandial blood sugar levels effectively.

Mechanism of Action

  • Enhancement of Insulin Secretion: GLP-1 binds to receptors on pancreatic beta cells, stimulating insulin release only when blood glucose is elevated, minimizing hypoglycemia risk.
  • Suppression of Glucagon: It inhibits glucagon secretion from alpha cells, reducing hepatic glucose output.
  • Delay of Gastric Emptying: By slowing gastric emptying, GLP-1 reduces the rate of glucose absorption, preventing rapid spikes in blood sugar.
  • Appetite Regulation: GLP-1 acts on the central nervous system to promote satiety, supporting weight loss efforts.

    • GLP-1 and Diabetes Pathophysiology

    In individuals with T2DM, the incretin effect is often diminished, leading to impaired insulin secretion and elevated blood glucose. This reduced GLP-1 activity contributes to the characteristic hyperglycemia of diabetes. Enhancing GLP-1 signaling has therefore become a strategic target in diabetes therapies.

    GLP-1-Based Therapies

    Several GLP-1 receptor agonists (GLP-1 RAs) and related agents have been developed to mimic or enhance GLP-1 effects. These therapies improve glycemic control, promote weight loss, and have cardiovascular benefits.

    Common GLP-1 Receptor Agonists

  • Exenatide: One of the first GLP-1 RAs, available as twice-daily or once-weekly injections.
  • Liraglutide: Daily injectable with proven cardiovascular benefits.
  • Dulaglutide: Weekly injectable, convenient dosing.
  • Semaglutide: Available as a weekly injection and recently in oral form; notable for significant weight loss effects.

    • Mechanism and Benefits

    GLP-1 RAs bind to GLP-1 receptors, stimulating insulin release and inhibiting glucagon. They also promote satiety and weight loss, crucial for many T2DM patients. Clinical trials have demonstrated improved HbA1c levels, reduced weight, and lower cardiovascular risk.

    Dosing and Administration

  • Dosing varies by agent; for example, liraglutide typically starts at 0.6 mg daily, titrating up to 1.2-1.8 mg daily.
  • Semaglutide oral dosing starts at 3 mg daily for 30 days, then increases to 7 mg daily, with the option to increase to 14 mg daily.
  • Patients should follow prescribed dosing and administration instructions carefully.

    • Practical Considerations

  • Side Effects: Common side effects include nausea, vomiting, and gastrointestinal discomfort. These often diminish over time.
  • Contraindications: Not recommended for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Monitoring: Regular blood glucose and HbA1c monitoring is essential.

    • Emerging Research and Future Directions

    Ongoing studies explore dual agonists targeting GLP-1 and other receptors (e.g., GIP) for enhanced metabolic effects. Oral formulations and combination therapies are expanding options for patients.

    Conclusion

    GLP-1 plays a central role in glucose metabolism, and therapies targeting this pathway offer effective management of type 2 diabetes. These treatments improve glycemic control, support weight loss, and reduce cardiovascular risk. However, individual responses vary, and healthcare provider guidance is crucial to optimize therapy and ensure safety.

    Important: Always consult a healthcare professional before starting or changing any diabetes treatment or peptide therapy to ensure it is safe and appropriate for your individual health needs.